Stroke Drug Development Targeting PSD-95

PSD-95 is involved in a variety of physiological and pathological activities in the brain. Under physiological conditions, PSD-95 is essential for neuronal function and survival, while under pathological conditions, PSD-95 is involved in the regulation of excitotoxicity and other process processes. It has been shown that PSD-95 plays an important role in the pathological process of stroke, and its expression levels appear extremely markedly altered within a short time of stroke onset. In view of this, Ace Therapeutics offers comprehensive services for stroke drug development targeting PSD-95 from different research perspectives to accelerate your stroke drug development research.

Development of Stroke Drugs Targeting The PSD–95-nNOS Complex

Disruption of the PSD-95-nNOS complex to stop its mediated excitotoxicity is an important pathway for the treatment of stroke, and new drugs targeting this pathway are currently entering clinical trials. Ace Therapeutics offers comprehensive services for the development of stroke drugs that disrupt the PSD-95-nNOS complex.

• Based on our ultra-large small molecules library, including compound libraries, natural product libraries, and fragment libraries, we obtain a large number of small molecule compounds or peptides that can disrupt the PSD-95-nNOS complex by computerized screening techniques.
• We validate the pharmacological activity of drug candidates against stroke by providing services such as neuronal cell activity assay, ion channel activity test, induced fear conditioning test, memory expression test, and pain test.

Development of PSD-95 Inhibitor as Stroke Drug

Activation of PSD-95 promotes excessive activation of NMDAR, which in turn promotes excitotoxicity exacerbating the stroke. Therefore, PSD-95 inhibitors could have a therapeutic effect on stroke by blocking this process.

• Based on our ultra-large small molecules library, including compound libraries, natural product libraries, and fragment libraries, we obtain PSD-95 inhibitors by virtual screening technique.
• We have established in vitro and in vivo models of NMDAR-induced excitotoxicity to investigate the effect of PSD-95 inhibitors on excitotoxicity.
• We have established different stroke models to further validate the therapeutic effects of drug candidates on stroke.
• We provide neuronal activity assay service, ion channel activity assay service, and various biomarkers assay services to validate the effect of PSD-95 inhibitors on the development of stroke.

Ace Therapeutics provides structural optimization services for various peptide drug candidates. We optimize peptide candidates for medicinal value through, peptide phosphorylation labeling, peptide protein coupling, C-terminal modifications, methylation and other alkylation modifications, and other pathways. In addition, we have developed different pharmacokinetic models to evaluate the physicochemical properties, absorption, distribution, metabolism, and excretion characteristics of the drug candidates. We also provide in vivo stability testing services for peptide drugs to ensure the effectiveness of the drug candidates.

If you would like to learn more about our services, please feel free to contact us.

1. Ugalde-Triviño, L.Díaz-Guerra, M., Psd-95: An effective target for stroke therapy using neuroprotective peptides. Int J Mol Sci, 2021. 22(22).
2. Qu, W., et al., Disrupting nnos-psd95 interaction improves neurological and cognitive recoveries after traumatic brain injury. Cereb Cortex, 2020. 30(7): p. 3859-3871.